the I appreciate morning. joining Good everyone time taking today. us
quarter both II, endpoints. III of and SEL-XXX studies met of a significant refractory positive Phase X DISSOLVE milestone which marked I first XXXX The by their of in was from with the results announcement of gout, primary chronic
candidates components. reminder, As consisting drug a of SEL-XXX a X product is combination
reduce urate serum disfiguring joint patients such refractory a tissue potent serious as and enzyme debilitating The has who deposits disease first observed have gout that pegadricase, in tophi. of component to symptoms been called uric pain continue to is
to rapamycin is used of the of as formation of to is drugs. the designed to that immune of tolerance the same proposed the that other drug which immunosuppression mechanism are interaction rather component The formulation time. commonly reduce at second immune candidate antibody system drugs than administered our condition ImmTOR, nano-encapsulate is is The induction with
mg arm and with single conventional identically every randomized total their treatment Patients of doses intervention globally. across randomized, I DISSOLVE as respective or placebo-controlled or II refractory X.X of to mg randomized per were dosed kg in kg. X XXX XX dosed and treatment subjects SEL-XXX per II U.S. Each evenly of the a double-blind, X DISSOLVE of subjects X.XX receives a in and total patients I X randomized days. DISSOLVE therapy. and designed, XXX arms, were a trials placebo, gout
with response, during met at monthly XX% was per I for its reduction primary serum kg, DISSOLVE end point, of which achieving per time of XX% month least at SEL-XXX mg the X and achievement a X. maintenance deciliter of as receiving doses urate below defined patients milligrams X.XX of
met receiving doses II SEL-XXX with per DISSOLVE of also response. a primary its at monthly endpoint, XX% kg, of mg patients achieving X.XX
the X.XX global of the dose Of SEL-XXX profile age in the older, also in and by study was encouraged in note, response the U.S. XX% per study. trials. the safety patients XX of rate kg years in the XX% observed mg We're very or of
for serve chronic SEL-XXX patients could flare did which gout. potentially suffering support refractory the no compared not reaction dosing SEL-XXX lowering incidence as of XX% these In to placebo. months infusion months to X.X% new very contrast The therapies, and high who increase other XX convenient U.S. X signals. rate group. subjects infusion therapeutic to safety from respond the option, that once-monthly with meaningful therapy continue a about urine excited dose new through of In notably We're a completed results, gout schedule no with was study, in reactions
and potential the submission our data, partner, U.S. this Based on commercialization is a in regulatory Sobi, for preparing
represents have the immune which, to as validation knowledge, of We and for these tolerance now serve approach, our platform data. data our ImmTOR technology, believed only long positive III the Phase in potential believe with
these year. at scientific data trials conference a We later this expect to full share from
trial by Sobi of first now decide and filing on to completed, next. the platform where take half the this track With BLA the to ImmTOR successfully our opportunity have we for XXXX,
with We profile approach unwanted program, expanding the to have the the applications immune and enabling of applications we associated for the tolerance existing improving autoimmune for solve challenges gene with disease. always drugs, appreciated tolerability in self-tolerance and from our multiple potential immunogenicity to as toughest saw therapy restoring SEL-XXX
recognize clinical development we market especially capital environment, be thoughtful to However, about the our in strategies. that we need and current allocation
key with the steps, recently extend focus have to programs We Board, where potential which we now believe our these a we our our cash on resources believe we highest XXXX. review walk that of to conducted Together you second into succeed. will half strategic the through, I'll runway
development the tolerance and which diseases of for of in tolerance patients selective IL, immune duration the ImmTOR autoimmune the our platform Trex of ImmTOR liver. First, ImmTOR proprietary candidate IL-X potential immune enhance to with further of and combines we magnitude to precision our IL treated prioritize has represents for diseases. plan evolution the
effects expansion suppression, of is vulnerable Specifically, these to cells of approach with vivo which serious standard T balance immune is versus broad restore side it are associated patients induction infection natural to and regulatory immune designed and the through system in malignancies. and
track initiate in on XXXX. IND-enabling for IL remain studies ImmTOR to We
additional will of in future on for parallel, to the we liver, focus assess development. and initial continue be diseases autoimmune indications Our
intend agreements. Astellas with our also and Sobi and to with work continue We SEL-XXX for Xork. support these include for our partnerships existing collaboration to prioritize the These under
filing, to to XXXX. expected of with SEL-XXX which is first we the work half Sobi continuing in prepare are the the For program, BLA
well net markets as as responsible payments are As to are royalties a in up our of and reminder, under inter and manufacturing, double-digit China. Sobi, Selecta commercial tiered we on entitled regulatory is to they million outside with agreement all responsible for activities in $XXX receive milestone for sales.
or disease result, in development its Xork, utilities. G will adults. patients high presence developed for is as preexisting of immunoglobulin treatment pathogens. partnership these the common cross-reactivity against currently investigational antibodies that a ineligible use Xork be through The AAV Pompe advancing Late-Onset to And main preexisting AAV-based the their with IgG clinical ATXXX, capsids. are low naturally Many for also with protease by We're antibodies due differentiated against is in Xork serum. human IgG therapies in to restrict protease occurring therapy prevalence trials gene of with can this of protease. Astellas our our derived next-generation antibodies to for investigational AAV human Astellas
to believe therapies gene the immunity against to potential activity addressing life-changing to we expand Due access Xork selective has protease Nabs, by preexisting AAV. anti-AAV to
are the or exploring of ways respect therapy our through gene to AAV of to development reimagine partnerships. with methylmalonic further Phase the SEL-XXX, MMA. gene With treatment remainder potential paused ImmTOR I/II these These have programs ongoing pausing therapy for study we alternative combined our include enrollment our assets, advance acidemia, of and of
for preserving in intended our the trial we the forward while the programs. near partners always believe path will inform Selecta's and And partner have allow therapy reimagine pausing gene clinical cash regulatory program, We to resources potential also this to term. any help
initiative, our to I'd all impacted like in our sincere initiative. were approximately we've privatization workforce headcount with our express those gratitude align our the priorities by and to XX% to my to order operations. undertaken of by connection with this In difficult who capital this decision reduce streamline
I'm to today. confident on that execute Selecta the outlined is priorities well positioned I've
ImmTOR We focus diseases. autoimmune our bring patients continue therapies to to leveraging new on platform to from suffering
financial of to turn With for over it the review Blaine that, results. a I'll
